← Leaderboards
Tianhong Yang
Biostrategies, Lc
$821,265
Attributed
$2,436,420
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,436,420 · 4
By mechanism
R44$1,500,000 · 1
R43$936,420 · 3
Top collaborators
- Carole L. Cramer4 shared
- Walter Acosta3 shared
- David Radin1 shared
Most similar at Biostrategies, Lc
Same institution · by research overlap
- David Radin$3,550,799
- Walter Acosta$3,031,644
- Jose Marcos Condori$207,935
Others in their field
Other Emerging Leaders on “Tissues”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$61,115,130
- Leonard Freedman · Leidos Biomedical Research, Inc.$54,559,980
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Evan Z Macosko · Broad Institute, Inc.$33,867,067
Research focus
TissuesFamilyPathologyAffectSmall Business Innovation Research GrantCessation Of LifeMammalian CellOrganPublic HealthUptakeGenetic DiseasesHealth SystemBindingDoseEnzymesLectinMouse ModelHeartHuman GeneticsGlycolipidsInfusion ProceduresChildBiodistributionChimeric Proteins
Grant awards (4)
Treatment of GM1 gangliosidosis CNS manifestations by AAV systemic expression of lectin-enhanced enzyme$1,500,000
R44 · FY2025 · NS
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases$295,923
R43 · FY2023 · HD
Krabbe disease therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat pathologies of the CNS$390,497
R43 · FY2022 · NS · contact PI
Treatment of muscular symptoms in Pompe rare disease via lectin assisted ERT delivery$250,000
R43 · FY2020 · AR